This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
CRESEMBA® achieves survival rates similar to amphotericin B in mucormycosis1
Liposomal amphotericin B was the only licensed antifungal agent for mucormycosis prior to the arrival of CRESEMBA®, which provided a much-needed alternative option.1,2
In a case-control analysis of patients with mucormycosis from the VITAL registration trial and matched case-controls from the FungiScope registry, survival was similar with CRESEMBA® and amphotericin B.1
a. Patients were censored on the day of their last known survival status (circles).
Adapted from reference 1.
CRESEMBA® was associated with an overall response of 11% (complete or partial response) at Day 42 (primary endpoint), rising to 31% (complete and partial response) at the end of treatment.1
Weighted all-cause mortality at Day 42 was not significantly different between CRESEMBA® and amphotericin B at 33% vs 41%, respectively (p=0.595).1
Single-arm, open-label, multicentre, international trial of CRESEMBA® in patients with rare fungal infections, including mucormycosis
Mucormycosis cases were matched with controls from the FungiScope registry who received AmB-based treatment
Primary endpoint: overall response at Day 42 as determined by an independent data review committee
b. Oral or IV loading regimen determined at the discretion of local investigators.
IV, intravenously; PO, per os (orally).
CI, confidence interval; HR, hazard ratio.
Prescribing Information:
CRESEMBA® (isavuconazole)
References:
PP-CRB-IND-0472 July 2022
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.